MiMedx Group, Inc. (NASDAQ:MDXG – Get Free Report)’s share price fell 7.5% during mid-day trading on Tuesday . The company traded as low as $6.89 and last traded at $6.89. 774,855 shares traded hands during mid-day trading, an increase of 1% from the average session volume of 769,048 shares. The stock had previously closed at $7.45.
Analyst Ratings Changes
A number of brokerages recently issued reports on MDXG. Mizuho boosted their price objective on MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Lake Street Capital started coverage on MiMedx Group in a report on Thursday, March 7th. They set a “buy” rating and a $12.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, MiMedx Group has an average rating of “Buy” and a consensus target price of $12.25.
MiMedx Group Stock Down 7.7 %
The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. The firm has a market cap of $1.01 billion, a PE ratio of 21.75 and a beta of 1.32. The stock has a fifty day simple moving average of $8.01 and a two-hundred day simple moving average of $7.69.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). MiMedx Group had a return on equity of 41.12% and a net margin of 14.49%. The business had revenue of $86.83 million for the quarter, compared to analysts’ expectations of $85.58 million. As a group, sell-side analysts expect that MiMedx Group, Inc. will post 0.33 EPS for the current fiscal year.
Insider Transactions at MiMedx Group
In other news, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total transaction of $162,028.95. Following the completion of the transaction, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Ricci S. Whitlow sold 15,493 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the completion of the transaction, the chief operating officer now owns 416,321 shares in the company, valued at $3,359,710.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 20,381 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the transaction, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,145 shares of company stock valued at $409,378. 19.90% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On MiMedx Group
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXG. AJOVista LLC purchased a new stake in shares of MiMedx Group in the fourth quarter worth $25,000. Squarepoint Ops LLC purchased a new stake in shares of MiMedx Group in the fourth quarter worth $28,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of MiMedx Group in the third quarter worth $38,000. Fairfield Bush & CO. purchased a new stake in shares of MiMedx Group in the second quarter worth $51,000. Finally, Delphia USA Inc. purchased a new stake in shares of MiMedx Group in the first quarter worth $55,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.